Eli Lilly Return on Tangible Equity 2010-2022 | LLY

Current and historical return on tangible equity values for Eli Lilly (LLY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Eli Lilly Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-06-30 $5.69B $-2.73B -209.09%
2022-03-31 $6.13B $-1.91B -183.43%
2021-12-31 $5.58B $-2.43B -136.80%
2021-09-30 $5.97B $-3.82B -123.89%
2021-06-30 $6.07B $-5.21B -111.47%
2021-03-31 $6.09B $-4.87B -102.65%
2020-12-31 $6.19B $-5.39B -91.01%
2020-09-30 $5.57B $-6.32B -75.75%
2020-06-30 $5.62B $-7.16B -74.65%
2020-03-31 $5.53B $-8.35B -72.59%
2019-12-31 $8.32B $-7.60B -110.63%
2019-09-30 $7.95B $-7.00B -226.99%
2019-06-30 $7.84B $-7.55B -3762.11%
2019-03-31 $6.26B $-7.93B 244.63%
2018-12-31 $3.23B $8.47B 52.94%
2018-09-30 $0.45B $6.17B 9.37%
2018-06-30 $-0.14B $3.52B -2.97%
2018-03-31 $1.12B $6.26B 21.22%
2017-12-31 $-0.20B $3.27B -4.05%
2017-09-30 $2.23B $6.32B 39.37%
2017-06-30 $2.45B $5.34B 42.09%
2017-03-31 $2.19B $5.20B 36.85%
2016-12-31 $2.74B $5.75B 44.45%
2016-09-30 $2.44B $6.97B 40.06%
2016-06-30 $2.47B $5.82B 41.09%
2016-03-31 $2.32B $6.10B 38.62%
2015-12-31 $2.41B $5.52B 40.19%
2015-09-30 $2.36B $6.57B 32.32%
2015-06-30 $2.06B $5.84B 23.18%
2015-03-31 $2.19B $6.05B 20.38%
2014-12-31 $2.39B $10.75B 18.71%
2014-09-30 $2.69B $12.93B 20.03%
2014-06-30 $3.39B $13.33B 25.49%
2014-03-31 $3.86B $14.15B 30.53%
2013-12-31 $4.68B $13.31B 40.02%
2013-09-30 $4.78B $12.44B 43.96%
2013-06-30 $4.91B $10.73B 46.62%
2013-03-31 $4.63B $10.34B 45.63%
2012-12-31 $4.09B $10.02B 41.13%
2012-09-30 $4.12B $11.03B 43.19%
2012-06-30 $4.03B $9.17B 43.60%
2012-03-31 $4.30B $9.56B 46.36%
2011-12-31 $4.35B $8.41B 47.29%
2011-09-30 $4.66B $9.84B 51.83%
2011-06-30 $4.73B $9.32B 55.25%
2011-03-31 $4.88B $9.20B 62.75%
2010-12-31 $5.07B $7.59B 71.61%
2010-09-30 $4.82B $8.10B 72.53%
2010-06-30 $4.45B $6.20B 72.36%
2010-03-31 $4.26B $6.43B 73.54%
2009-12-31 $4.33B $5.83B 83.94%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.922B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22